Wandercraft

Summary

About

About Wandercraft

Atalante X uses powered hip, knee and ankle joints with active balance control to support hands-free gait rehabilitation. Therapists can select walking patterns and assistance modes for patients with severe gait impairments, including people who cannot rely on crutches or upper-body support.

Eve applies the same self-balancing principle to personal mobility at home and in the community. Wandercraft is building a continuum from clinical rehabilitation with Atalante X to upright everyday movement with Eve, alongside distribution and regulatory programmes for consumer access.

PRICE
Range 1Y
Return
High
Low
Updated
DATA: KORTHOS

Articles

16 OCT 2026

Wandercraft opens Paris production site as Calvin-40 humanoid programme scales

09 SEPT 2026

Humanoid production and supply chain — 2–9 September 2026

04 SEPT 2026

Wandercraft Says Calvin-40 Has Secured 12 Blue-Chip Customers

12 MAR 2026

Renault prepares Calvin humanoids for factory work with Wandercraft

Products

Deployments

  • Operating use

    2026-10-01 - Atalante X and EksoNR together support patients at more than 700 rehabilitation centers worldwide. - Combined Atalante X and EksoNR reach, not either product alone

    Source

Supply

Supply chain relationships

  • Elmo Motion Control

    Inbound - Compute & Control - Elmo supplies 12 Twitter servo-drive modules that control multiple articulations in Wandercraft exoskeleton systems

    Source
  • NVIDIA

    Inbound - Compute & Control - Wandercraft states Calvin-40 integrates the NVIDIA Jetson edge AI platform

    Source

Funding

Investors

  • Quadrant Management - Lead - Angel / Individual - 2 funding events - repeat backer - first seen 2022-01-19 - latest 2025-06-11
  • AG2R LA MONDIALE - Participant - Unknown - 1 funding event - first seen 2025-06-11
  • Bpifrance - Participant - Unknown - 1 funding event - first seen 2022-01-19
  • Cemag Invest - Participant - Angel / Individual - 1 funding event - first seen 2025-06-11
  • LBO France - Participant - Angel / Individual - 1 funding event - first seen 2025-06-11
  • Martagon Capital - Participant - VC - 1 funding event - first seen 2025-06-11
  • Mutuelles Impact - Participant - Angel / Individual - 1 funding event - first seen 2025-06-11
  • PSIM fund managed by Bpifrance - Participant - VC - 1 funding event - first seen 2025-06-11
  • Renault Group - Participant - Angel / Individual - 1 funding event - first seen 2025-06-11
  • Teampact Ventures - Participant - VC - 1 funding event - first seen 2025-06-11
  • XAnge - Participant - Unknown - 1 funding event - first seen 2025-06-11

Team

  • Matthieu Masselin - Co-founder - Co-founder connected to Wandercraft's self-balancing exoskeleton and rehabilitation robotics development.
  • Alexandre Boulanger - Co-founder - Co-founder associated with Wandercraft's robotic exoskeleton development and self-balancing mobility technology.

Timeline

Events

  • 2026-10-01 - Acquisition - Wandercraft completes acquisition of Ekso Bionics operating business

    Atalante X and EksoNR together support patients at more than 700 rehabilitation centers worldwide. Wandercraft intends to keep supporting Atalante X, EksoNR, Eve and Indego Personal. Both boards unanimously approved the transaction, combining Wandercraft’s EMEA position with Ekso’s U.S. clinical and commercial reach.

    Source
  • 2026-09-17 - Product Launch - Wandercraft commercially launches Eve exoskeleton in the U.S.

    Eve is the first FDA-cleared personal exoskeleton without restrictions based on the neurological level of spinal cord injury, extending eligibility beyond previously cleared devices. National Seating & Mobility, Wandercraft's exclusive Complex Rehabilitation Technology distribution partner for Eve, will support evaluation, education, access and delivery through a network of more than 180 locations. Medicare covers qualifying personal exoskeletons as custom-fitted orthoses under HCPCS billing code K1007, with Department of Veterans Affairs access via USVetServ, workers' compensation programmes and self-pay financing options also in place.

    Source
  • 2026-09-04 - Market Signal - Wandercraft secures 12 Calvin-40 customers

    Initial development targets handling boxes, parcels, tyres, panels and carts across industrial and logistics workflows. Finer picking and sorting functions were being developed and tested as extensions to larger-object handling. The production programme draws on Renault Group’s manufacturing, procurement and design-to-cost expertise.

    Source
  • 2026-08-11 - Regulatory - Wandercraft receives FDA clearance for Eve personal exoskeleton

    Eve is intended for level indoor surfaces and level surfaces in immediately adjacent open-air areas such as patios and terraces, under the supervision of a specially trained companion. The clearance builds on Atalante X, Wandercraft's self-balancing rehabilitation exoskeleton used in more than 150 rehabilitation and research centres worldwide. Medicare has provided a reimbursement pathway for eligible personal exoskeleton users under DMEPOS billing code K1007 since 2024, with Wandercraft anticipating Eve could become eligible within 60 to 90 days.

    Source
  • 2026-07-27 - Regulatory - Ecuador authorises Wandercraft Atalante X for clinical rehabilitation

    The authorised uses cover rehabilitation associated with spinal-cord injury, stroke-related hemiplegia and multiple sclerosis. Clínica de Lesiones Deportivas in Quito is the first announced Ecuador installation site. The clinic describes Atalante X as forthcoming in 2026; authorisation is not represented as an already operating installation.

    Source
  • 2026-03-12 - Deployment - Renault Group deploys 350 Wandercraft Calvin-40 humanoid robots

    • Renault Group deployed 350 Wandercraft Calvin-40 humanoid robots in its factories over an 18-month period. • The robots performed physically demanding tasks, such as hauling tires, at the Douai factory's supply line. • This deployment followed a strategic partnership and minority investment by Renault Group in Wandercraft.

    Source
  • 2026-03-12 - Deployment - Wandercraft Calvin-40 trials tyre handling at Renault Douai

    Renault planned to add another 350 humanoids over the following 18 months. Calvin-40 was described as the second iteration, with AI training doubling its speed over six months. The programme followed Renault’s strategic partnership and minority investment in Wandercraft.

    Source
  • 2025-11-12 - Partnership - SAPA and Wandercraft agree Calvin-40 manufacturing partnership

    The first implementation phase targets precise, repetitive movement of large and heavy parts. The companies will co-develop applications around high-throughput manufacturing workflows before scaling across tasks and locations. The agreement extends Wandercraft’s industrial programme from its Renault Group OEM partnership to an Italian Tier 1 automotive supplier.

    Source
  • 2025-06-11 - Funding - Wandercraft secures US$75M funding and financing package

    Major contributors included Renault Group, the PSIM fund managed by Bpifrance, Teampact Ventures and Quadrant Management. Other participants included LBO France, Mutuelles Impact managed by XAnge, Cemag Invest, Martagon Capital and AG2R La Mondiale. The package supports an Eve market launch as early as 2026, wider Atalante X adoption and Calvin-40 development.

    Source
  • 2024-02-13 - Regulatory - Wandercraft's Atalante X receives second FDA clearance

    • Wandercraft received FDA clearance for Atalante X for rehabilitation in individuals with spinal cord injuries at levels T5 to L5. • This follows the device's previous clearance for stroke rehabilitation in December 2022. • The clearance is supported by data from over 500 patients, including clinical trials and real-world evidence.

    Source
  • 2023-12-28 - Market Signal - Wandercraft receives EUR 25M EIB loan

    The EIB loan supports development of Wandercraft's personal exoskeleton and access to Atalante X. The financing benefits from an InvestEU guarantee. The transaction is debt financing rather than a private-equity round.

    Source
  • 2022-01-19 - Funding - Wandercraft closes $45M Series C

    Quadrant Management led the round, with existing investor Bpifrance also participating. Wandercraft allocated the capital to U.S. expansion and continued development of its self-balancing mobility systems. The later 2025 Wandercraft Series D announcement independently identifies the preceding Series C as $45 million.

    Source

Relations

Relationships

  • Renault Group

    Deployment Partner - Wandercraft deployed its Calvin humanoid exoskeleton at Renault Group manufacturing facilities for worker assistance.

  • Ekso Bionics

    Acquired Company - Wandercraft acquired the Ekso Bionics operating business from a ChronoScale Holdings subsidiary in a signed-and-closed transaction.

  • SAPA

    Calvin 40 Application Development Partner - Wandercraft and SAPA agreed to develop and introduce Calvin-40 applications in SAPA manufacturing operations.

  • New York University

    Robotics Research Industry Partner - NYU's Center for Robotics and Embodied Intelligence maintains an industry partnership with Wandercraft.

Context

Comparable profiles

Shared workflows

Context tags

  • Rehabilitation robotics workflow - Workflow
  • Medical exoskeletons - Peer Group
  • Gait rehabilitation - Workflow
  • Exoskeleton gait training - Workflow
  • Self-balancing mobility control - Capability
  • Rehab exoskeleton OEM - Stack Layer
  • Rehabilitation robotics platform - Stack Layer
  • Rehab exoskeleton builder - Peer Group
  • Self-balancing rehab exoskeleton builder - Peer Group
  • Powered limb assistance - Capability
  • Home assistive care - Customer Environment
  • Rehabilitation clinics - Customer Environment